Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine։
”Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Patients with DVT or PE were randomly assigned in a 1:1 ratio to rivaroxaban 15 mg twice daily for 21 days, apixaban 20 mg/day or apixaban 10 mg twice daily for 7 days, followed by apixaban 5 mg twice daily, both groups for 3 months.
The primary outcome (PO) was clinically relevant bleeding (CRB), a composite of clinically relevant non-major bleeding (CRNMB) or clinically relevant non-major bleeding according to the ISTH, and major bleeding (MB). The secondary outcomes (SO) were the individual components of the primary PE: recurrent DVT/PE.
CRB was observed in 3.3% with Apixaban versus 7.1% with Rivaroxaban (Relative Risk: 0.46; 95% CI, 0.33 to 0.65; P<0.001). MB 0.4% versus 2.4%; Relative Risk: 0.16; 95% CI, 0.06 to 0.40.
The percentage of DVT/PE recurrence was similar in the two treatment groups at 3 months
These data cannot be extrapolated to atrial fibrillation; the COBBRA-AF study on atrial fibrillation is currently underway.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis